When Relief Is the Only Door Open

When pain lasts only a few days, the most obvious door is often the right one to open: take an analgesic, if necessary, rest, and give the body time to recover. Medication is well suited to that purpose. The difficulty begins when pain ceases to be a passing event and becomes an enduring condition, recurring over weeks, months, or years until it is woven into the ordinary fabric of a person’s life. At that point, pharmacological relief assumes a different role, although the implications of that shift are not always fully explained to the person reaching for the next dose. What began as a temporary bridge becomes the baseline; occasional use becomes daily treatment; medication intended to carry someone through recovery becomes a prolonged exposure whose risks may increase with dose, duration, and individual vulnerability. These risks include gastrointestinal ulceration and bleeding associated with long-term NSAID use, liver injury associated with excessive acetaminophen intake, tolerance and physical dependence during long-term opioid therapy, sedation or cognitive impairment caused by certain analgesics and, in some cases, addiction (Busse et al., 2017 ; Canadian Pain Task Force, 2020). Medication plainly belongs in pain management. The more difficult question is why it so often becomes the only option presented, while patients hear remarkably little about the other forms of care available to them.

Roughly one in five Canadians lives with chronic pain—nearly eight million people contending each day with symptoms that vary widely in intensity, origin, and duration (Canadian Pain Task Force, 2020). Despite the scale of the problem, the response available through the health care system remains remarkably limited, reflecting the structure of care as much as the state of clinical knowledge. Routine medical appointments in Canada often last fifteen minutes or less, a constraint that necessarily determines what can be examined within them. Identifying the biomechanical factors that contribute to recurring low back pain, tracing the relationship between compensatory movement patterns and chronic neck stiffness, or assessing the relationship between sleep disruption and prolonged stress and an inflammatory condition requires time, interdisciplinary collaboration and follow-up over several visits. Prescribing medication can be accomplished within the initial consultation, giving pharmacological treatment an administrative advantage over approaches that depend on sustained assessment and rehabilitation. When remuneration models favour a greater volume of shorter consultations, interdisciplinary pain services remain scarce and unevenly distributed, and waiting periods for specialized care extend for months. Medication then becomes the default response—not necessarily because it offers the most complete treatment, but because it is the intervention that the system is organized to provide most efficiently (Canadian Pain Task Force, 2020; Gatchel et al., 2007).

The pharmaceutical industry has a substantial and well-documented financial interest in the centrality of medication to pain care. Global sales of over-the-counter analgesics, prescription anti-inflammatories, and opioid formulations amount to tens of billions of dollars annually, and commercial incentives on that scale inevitably influence research priorities, marketing practices, prescribing culture, and the way pain is presented to both clinicians and the public. Canada’s opioid crisis offers the clearest illustration of what can occur when pharmaceutical promotion overtakes clinical prudence. During the late 1990s and early 2000s, opioid analgesics were marketed aggressively amid assurances that gravely understated their potential for addiction, contributing to a dramatic expansion in prescribing and helping to create the conditions from which the present crisis emerged. That crisis has since evolved and is now driven largely by fentanyl and other substances in the unregulated drug supply, but its toll remains staggering: more than 56,000 apparent opioid-toxicity deaths were recorded in Canada between 2016 and 2025 (Public Health Agency of Canada, 2026). Purdue Pharma Canada, whose promotion of OxyContin played a significant role in expanding opioid prescribing, agreed to a settlement of $150 million with the Canadian and provincial governments to offset a portion of the resulting health care costs, an amount bearing little proportion to the damage accumulated across families, communities, and public institutions. History exposes a structural conflict between commercial objectives that reward continuing pharmaceutical sales and prudent prescribing practices that may reduce reliance on those products, particularly when effective care may instead involve manual therapy, movement-based rehabilitation, psychological support, or behavioural intervention. The resources devoted to promoting physiotherapy and yoga therapy bear no comparison to the multibillion-dollar marketing machinery of the pharmaceutical industry; their more limited visibility reflects their economic structure far more than the therapeutic value they may offer.

Understanding why other approaches merit serious consideration requires examining what chronic pain involves within the nervous system, because the experience encompasses far more than the transmission of signals from injured tissue. In 2020, the International Association for the Study of Pain revised its definition of pain as “an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage,” making explicit a principle that decades of pain research had progressively established: the intensity and persistence of pain cannot be inferred solely to the extent of an identifiable injury (Raja et al., 2020). The gate control theory proposed by Melzack and Wall (1965) had already transformed the field by suggesting that nociceptive messages travelling toward the brain are modulated within the spinal cord and influenced by other sensory input, descending neural activity, attention, and context. Ronald Melzack, working at McGill University, later expanded this framework through the neuromatrix theory, which described pain as an experience emerging from the brain’s integration of sensory information with cognitive, emotional, and physiological processes, rather than as a direct measurement of tissue damage (Melzack, 2001). This distinction becomes particularly important when pain persists beyond the expected period of recovery or continues in conditions such as fibromyalgia, nonspecific chronic low back pain, osteoarthritis, and neuropathic disorders, where the relationship between tissue pathology and the severity of the pain experienced may become increasingly complex. Central sensitization represents one mechanism through which this can occur: neural pathways involved in processing potentially threatening stimuli become more responsive, lowering pain thresholds and sometimes causing ordinarily innocuous sensations, such as light touch, sustained pressure, or a change in posture, to be experienced as painful (Woolf, 2011). Medication can reduce nociceptive input, inflammation, or amplified signalling, depending on the drug and the condition being treated, while other influences may continue to sustain the experience of pain. Protective movement patterns can perpetuate muscular tension and inefficient loading; the expectation that pain invariably signals further damage can encourage activity avoidance and the progressive loss of strength and mobility; disrupted sleep can weaken endogenous pain-modulation systems; persistent inflammation can heighten neural sensitivity. Addressing these interacting influences requires a wider therapeutic response than pharmacological relief alone can provide (Nijs et al., 2014; Vlaeyen & Linton, 2000).

This is where the discussion of other approaches properly begins: persistent pain is a multidimensional phenomenon and therefore calls for a response capable of addressing more than one of its contributing mechanisms. Exercise and structured physical activity are among the most extensively studied interventions in populations living with chronic pain. An overview of Cochrane Reviews found that physical activity may produce modest reductions in pain severity while improving physical function and quality of life across conditions that include fibromyalgia, rheumatoid arthritis, and chronic low back pain. Although the quality of the evidence was often limited, the magnitude of benefit varied, and maintaining participation remained a recognized challenge (Geneen et al., 2017). The physiological basis for these effects is well established. Exercises in which resistance, duration, and complexity increase gradually can strengthen the muscles supporting vulnerable joints, improve cardiovascular capacity and muscular endurance, preserve joint mobility, facilitate the movement of synovial fluid, and engage endogenous pain-modulation systems, including descending inhibitory pathways and the release of endogenous opioids. Their importance becomes clearer when one considers the cycle they can interrupt. When pain persists, the natural response is often to protect the affected region, avoid movements that provoke discomfort, and rest in the expectation that reduced activity will permit healing. Such protection serves an obvious purpose after an acute injury; when it continues beyond the period in which the tissues require it, strength, mobility, endurance, and confidence in movement may gradually decline. Ordinary activities then demand a greater proportion of the body’s available capacity, compensatory patterns develop, and movements that once felt manageable become more difficult or painful, reinforcing the original impulse to avoid them. The cycle sustains itself, as pain restricts activity, inactivity reduces physical capacity, and diminished capacity makes activity increasingly taxing. Taking painkillers can provide enough relief to allow movement to resume. However, the functional benefit will depend on using this opportunity to restore what inactivity has worn away. A carefully graded exercise program can reverse this trajectory by restoring muscular and articular support, improving the efficiency of movement, increasing tolerance for physical demands, and gradually weakening the nervous system’s association between activity and threat. For chronic primary low back pain, one of the leading causes of disability worldwide, current clinical guidance places structured exercise within a broader, person-centred program of care while advising against the routine use of opioid analgesics, reflecting the central role of active rehabilitation in restoring function over time (World Health Organization, 2023).

Physiotherapy occupies a central position within this therapeutic landscape because its distinctive contribution lies in the individualized assessment of the mechanical, neurological, and functional factors associated with a particular pain presentation. A physiotherapist evaluating persistent subacromial shoulder pain, for example, may examine the movement of the shoulder blade, the strength and coordination of the rotator-cuff muscles, the mobility of the cervical and thoracic spine, the person’s tolerance for load, and the compensations that have developed around painful movements. Treatment can then combine manual techniques intended to improve joint mobility, progressive strengthening of muscles whose contribution has diminished, retraining of inefficient movement patterns, and adaptations to activities that repeatedly aggravate the symptoms, with each element adjusted according to the person’s condition, response, and functional goals. Access to this form of care remains markedly uneven across Canada. Eligibility for physiotherapy financed through provincial health insurance varies by jurisdiction and is often restricted according to age, diagnosis, income, care setting, or recent hospitalization, leaving many adults dependent on collective insurance plans or direct payment. Even when collective coverage is available, annual limits may cover only a small number of appointments, well short of what a sustained rehabilitation program can require. The resulting disparity is predictable: people who could benefit substantially from active rehabilitation may be unable to afford enough treatment to achieve it (Canadian Pain Task Force, 2020). Medication consequently remains easier to obtain within the existing system, since the medical consultation is insured and some portion of the prescription may be covered through a provincial drug program, workplace benefits, or private insurance, whereas physiotherapy usually entails a series of separately billed appointments whose cost continues for as long as the rehabilitation requires.

Massage therapy engages a dimension of the pain experience that is simultaneously tactile, neurological, and autonomic, involving both the processing of sensory information and the systems that regulate involuntary functions such as heart rate, digestion, and physiological responses to stress. Popular discourse often relegates massage to relaxation and treats it as a luxury rather than a form of care, although clinical research suggests that it can provide short-term relief from pain and functional limitations in some chronic musculoskeletal conditions. A Cochrane Review examining massage for low back pain found low-quality evidence of short-term improvements in pain and function among people with chronic symptoms, while emphasizing that the available trials were small and heterogeneous and that confidence in the results remained limited (Furlan et al., 2015). Its possible effects extend beyond the mechanical pressure applied to muscles and connective tissues. Touch and sustained pressure stimulate sensory receptors in the skin, fascia, and muscle, producing afferent input that can modulate nociceptive processing within the spinal cord and brain in a manner consistent with the gate-control principles described by Melzack and Wall. Massage may also produce temporary changes in autonomic activity, muscular tone, perceived stress, and the sense of physical safety, although these responses vary among individuals and cannot be reduced to a single mechanism. For someone whose pain has made the body seem unpredictable, and whose attention has gradually become organized around guarding particular regions or anticipating danger from ordinary sensations, the experience of controlled and tolerable touch may help restore a less adversarial relationship with the body. Its therapeutic value can therefore extend beyond immediate physical relief by allowing sensation to be encountered as information rather than interpreted automatically as a warning of further harm.

Yoga therapy operates at the intersection of several mechanisms relevant to persistent pain by combining adapted movement, respiratory regulation, attentional practices, and methods intended to influence autonomic activity. Most clinical trials have examined structured yoga programs rather than individualized yoga therapy, but their findings remain relevant because the two share the deliberate integration of posture, movement, breathing, and focused attention. A meta-analysis of ten randomized trials involving people with chronic low back pain found improvements in pain and back-specific disability over both shorter and longer follow-up periods, supporting yoga as an additional component of care rather than merely a form of general exercise (Cramer et al., 2013). Yoga therapy extends this foundation by adapting practices to the person’s symptoms, functional capacity, medical condition, and response over time, distinguishing it from yoga pursued principally as physical recreation, spiritual practice, or the performance of demanding postural sequences. Its respiratory component may contribute to pain regulation through several interacting pathways: diaphragmatic movement influences pressure within the abdominal cavity and the coordination of the trunk; changes in respiratory rate and depth alter carbon dioxide levels and the chemoreceptor signals generated in response to them; and the neural circuits governing respiration interact with autonomic, emotional, and attentional networks in the brain. Slower, controlled breathing may support parasympathetic regulation, in which the vagus nerve plays an important role, while meditative practices can reduce rumination, catastrophizing, and anticipatory anxiety that often intensifies the experience of chronic pain. For people whose nervous systems have developed a heightened sensitivity to ordinary sensations, the combined use of carefully graded movement, breathing, and attention can create repeated experiences of physical activity occurring without escalating threat, gradually expanding tolerance while reducing the arousal and apprehension that have become associated with movement. Research into yoga’s effects on physical and psychological health, including pain-related outcomes, supports its inclusion as a complementary element within a broader pain-management strategy, particularly when the practices are adapted to the person rather than imposed through a standardized sequence (Büssing et al., 2012).

Self-myofascial release—a form of self-massage in which sustained compression, movement, and shear are applied to muscle and connective tissue with specialized tools—extends some elements of professionally administered manual therapy into personal practice. In my own work, it takes the form of therapy balls of varying sizes and densities, which I use personally and am learning to employ as teaching tools through my training with TuneUp Fitness. Fascia is living, innervated, vascularized, and mechanically responsive tissue whose properties can change under pressure, movement, and load. The loose connective tissue between fascial layers contains hyaluronan, a substance whose viscosity influences how readily those layers glide against one another; changes in its distribution and aggregation have been associated with increased tissue density, reduced gliding, stiffness, and pain. Sustained pressure, shear, movement, and the resulting changes in tissue temperature and fluid distribution can influence these properties, producing genuine alterations within the fascial system alongside the neurological effects created by sensory stimulation (Stecco, 2015; Lesondak, 2025; Lesondak & Akey, 2025). Pressure also activates receptors involved in proprioception, muscular tone, and nociceptive processing, allowing the mechanical and neurological effects of the practice to operate together rather than as competing explanations. Research on self-myofascial techniques has found short-term improvements in range of motion and reductions in perceived muscle soreness following exercise, generally without impairing strength or physical performance, although much of the published literature has examined foam rollers and roller massagers rather than therapy balls specifically (Cheatham et al., 2015; Wiewelhove et al., 2019). The practical value of therapy balls also lies in their precision and accessibility: their dimensions allow pressure to be directed toward smaller or less accessible regions, while their different densities permit the intensity to be adjusted to the user’s tolerance. A set costs considerably less than a course of physiotherapy and can be used between appointments to address localized tension and discomfort, preserve mobility, and continue aspects of a professionally guided movement practice. My training is developing both the technical knowledge required to apply these methods appropriately and the pedagogical skills needed to teach them, positioning self-myofascial release as one component of a broader approach that includes movement, breathing, education, and professional treatment.

Physiotherapy, massage therapy, yoga therapy, self-myofascial release, and progressive exercise share an orientation that broadens pain management beyond the immediate reduction of symptoms. Medication may decrease nociceptive signalling, reduce inflammation, or alter the neurological processes involved in pain, depending on the drug and the condition; active and hands-on therapies examine additional factors that influence how the body moves, functions, and responds over time. These may include a protective movement pattern that distributes load unevenly through the spine, diminished hip strength that increases the demands placed on the hamstrings and lower back, respiratory habits associated with sustained physiological arousal, or the expectation that every painful sensation indicates further damage, which can lead to increasingly restricted activity and a gradual loss of strength, mobility, and confidence. Such patterns are rarely revealed in full during a fifteen-minute appointment. They emerge through careful assessment, repeated observation, trial and adjustment, and a therapeutic relationship in which the person contributes to identifying the factors affecting their pain and testing the changes most likely to improve function. This form of participation requires time, regular attendance, practice between appointments, and persistence to continue through setbacks and periods in which progress appears to have stalled. Chronic pain can deplete precisely the physical, emotional, and financial resources that such work demands, making the appeal of faster and less burdensome relief entirely understandable. Patients nevertheless deserve a clear explanation of what each approach can accomplish: medication may create a necessary period of relief, while rehabilitation uses that opportunity to rebuild capacity, restore movement, and develop ways of managing symptoms beyond the duration of a dose. Without that explanation—and without realistic access to the services required—the structure of the health care system effectively determines the treatment before the patient has been given a meaningful choice.

The structural barriers to this understanding are substantial. Pain neuroscience education explains how pain is produced and modulated within the nervous system, why its intensity does not always correspond directly to the extent of tissue damage, and how neural sensitivity can change over time. When incorporated into physiotherapy and combined with movement-based rehabilitation, it has been associated with reductions in pain, disability, fear of movement, and catastrophizing, particularly by helping people interpret physical sensations with less apprehension and participate more confidently in activity (Louw et al., 2016). Delivering this form of education requires time, however, and it remains difficult to accommodate within primary care appointments organized around brief assessment, diagnosis, and immediate treatment. Remuneration structures generally provide little room for an extended explanation of pain physiology, while access to physiotherapists and multidisciplinary programs equipped to offer that education remains limited by cost and availability. The result is a pronounced informational asymmetry. Medication reaches patients through a standardized system of prescribing, regulated labelling, written dosage instructions, and pharmacist counselling; whereas knowledge about exercise, manual therapy, respiratory regulation, sleep, nutrition, stress, and the psychological dimensions of pain must be assembled across appointments with different practitioners—when those services are accessible at all. Commercial promotion widens that disparity further: pharmaceutical products are supported by manufacturers with the resources and established channels to circulate information about their use, while nonproprietary interventions such as movement, breathing, sleep improvement, and pain education have no comparable source of promotion. The imbalance thus reflects more than the relative strength of the evidence; it reflects which forms of care are built into routine clinical practice, which professionals are compensated for explaining them, and which interventions possess an industry capable of keeping them continuously visible.

My engagement with these questions is rooted in personal experience. My mother was prescribed opioids following surgery, and when the postoperative pain subsided but other pain persisted, it was given the name fibromyalgia and the prescription continued. Over time, her use escalated: a faster-acting opioid formulation replaced the tablets she had previously taken, a supply intended to last a month was consumed in a fraction of that time, and she supplemented it with whatever over-the-counter analgesics she could obtain. What I remember most is not a single incident but the rhythm of a life increasingly organized around the prescription cycle, with days of sedation and confusion followed by agitation and distress as the medication ran out, until the person I knew seemed to disappear somewhere between the doses and the dates on which they could be renewed. Her pain was real, and medication had begun as an answer to an entirely understandable need for relief; over time, however, it became part of another destructive problem. Other possibilities may have existed, but no one presented them to her with the immediacy, authority, or accessibility of another prescription, leaving her with one readily available response even as it created suffering of its own. She later suffered a stroke that left her profoundly impaired for four years before she entered a coma from which she never recovered. We were not close, and I have no desire to romanticize the relationship we had, but watching someone you love disappear—first within a cycle governed by pain and medication, and later through the consequences that followed—creates a particular form of grief whose force does not depend on intimacy. Years later, persistent pain in my own body was also given the name fibromyalgia, a diagnosis that accounted for some symptoms while leaving others unexplained, particularly when inflammatory and psoriatic manifestations subsequently appeared in ways that the original diagnosis had neither anticipated nor encompassed. Whether those developments represented a progression of the same condition, an incomplete diagnosis, or the later emergence of an autoimmune process is a question I cannot answer retrospectively. The experience nevertheless left me with a lasting conviction that a diagnosis should open an inquiry as often as it concludes one, and that the management of persistent pain should extend beyond the suppression of symptoms to examine the factors—including movement quality, inflammatory activity, nervous-system regulation, continuity of sleep, and nutritional status—that influence how the body functions and changes over time.

My training in self-myofascial techniques has given this orientation a practical form. The therapy balls I am learning to use and teach are modest, adaptable tools that allow pressure to be directed toward particular tissues, intensity to be adjusted according to individual tolerance, and elements of self-care to continue between professional appointments. Their value lies partly in returning a measure of control to the person experiencing pain, who can determine where pressure is applied, how much is tolerable, and whether the resulting sensation or movement changes. When incorporated into a broader framework that includes yoga therapy, breathwork, and progressive movement, these methods expand the ways in which a person can respond to pain by exploring the interaction among tissue condition, sensory input, respiration, movement, and nervous-system activity. This orientation reflects the foundational philosophy of TRIVENA: physiological systems interact continuously; nutrition, movement, sleep, and emotional state participate directly in the conditions under which the body functions; and health over time depends partly on developing the knowledge and practical capacity to observe, understand, and participate in one’s own care. Medicine operating at its fullest capacity should encompass the complete range of evidence-supported options and place pharmacological treatment within a wider therapeutic strategy rather than allowing speed of prescription and ease of reimbursement to determine the care a person receives. Active approaches undeniably ask more of someone already burdened by pain, including time, effort, repetition, and the willingness to continue through uneven progress, but they can also offer something that symptom relief alone cannot provide: greater physical capacity, confidence in movement, and skills that remain available beyond the duration of any single treatment. A person living with persistent pain deserves to know that these possibilities exist and to receive meaningful support in pursuing them, because the work invested in restoring function is an investment in the body they will inhabit for the rest of their life and should be treated as an essential component of care rather than an optional service reserved for those with the means to obtain it.

Judicious pharmacological treatment retains an essential place in pain management. Acute injuries, postoperative recovery, palliative and end-of-life care, and severe exacerbations of chronic pain can all warrant appropriate analgesia, and withholding an indicated medication in such circumstances can cause substantial harm. Failure occurs when medication becomes the only modality presented to people whose pain is persistent or recurrent and is unlikely to resolve through pharmacological treatment alone. Evidence-supported options already appear throughout systematic reviews, meta-analyses, and clinical practice guidelines, and are delivered by physiotherapists, massage therapists, certified yoga therapists, and other practitioners trained within their respective professional frameworks to assess individual needs and adapt treatment according to the person’s response. These approaches generally require repeated appointments, practice between sessions, and a greater immediate investment of time and money than filling a prescription, particularly in Canada, where medication may be reimbursed through provincial drug programs or collective insurance plans, while coverage for physiotherapy, massage therapy, and other allied health services remains inconsistent and frequently inadequate. Their costs are therefore concentrated and highly visible to the patient, whereas the expenses associated with prolonged pharmaceutical management are distributed across insurance plans, public programs, repeated consultations, and the cumulative treatment of adverse effects. Research supports the capacity of exercise, pain education, and other active approaches to reduce symptoms and improve physical function in several chronic pain conditions, although outcomes vary and no single intervention provides a universal solution (Geneen et al., 2017; Louw et al., 2016). The relevant comparison is, therefore, between pharmacological relief used in isolation and relief incorporated into a broader strategy intended to restore movement, function, confidence, and participation in daily life.

The necessary recalibration begins with recognizing that medication’s position as the default response to persistent pain is sustained as much by the organization, financing, and commercial influences surrounding health care as by clinical evidence. The pharmaceutical industry has contributed treatments that relieve immense suffering while also engaging in practices whose consequences have devastated individuals, families, and entire communities; both realities belong within an honest account of modern pain management. Progress now depends on placing medication within a broader framework of active, participatory, and evidence-grounded care. To implement this framework, individuals must have access to physical therapy, regardless of their financial situation. Additionally, physicians must be able to devote the necessary time and compensation to addressing movement, sleep, stress, and functionality during routine care. Furthermore, education on pain management should be available before symptoms persist and treatment attempts fail, ultimately leading to a referral to a specialized clinic. Exercise, manual therapy, yoga therapy, respiratory practices, and carefully taught methods of self-care should be presented alongside pharmacological treatment as components of a strategy capable of responding to the biological, neurological, psychological, and social dimensions of persistent pain. The objective remains relief, but relief should also create opportunities to investigate treatable contributors, restore function, rebuild physical capacity, and help people participate more fully in their lives. Medication can remain one door through which relief is reached; it should cease to be the only door the health care system knows how to open.

References

British Columbia Ministry of Attorney General. (2022, June 29). Settlement reached with Purdue Pharma (Canada) for opioid damages. Government of British Columbia. https://news.gov.bc.ca/releases/2022AG0044-001031

Büssing, A., Michalsen, A., Khalsa, S. B. S., Telles, S., & Sherman, K. J. (2012). Effects of yoga on mental and physical health: A short summary of reviews. Evidence-Based Complementary and Alternative Medicine, 2012, Article 165410. https://doi.org/10.1155/2012/165410

Busse, J. W., Craigie, S., Juurlink, D. N., Buckley, N. A., Wang, L., Couban, R. J., Agoritsas, T., Akl, E. A., Huang, W., Irfan, M., Lamontagne, F., Mergiya, H., Patel, S., Rao, S., Selva, A., Singh, A., Sivananthan, L., Tsertsvadze, A., Wong, J. J., … Guyatt, G. H. (2017). Guideline for opioid therapy and chronic noncancer pain. CMAJ, 189(18), E659–E666. https://doi.org/10.1503/cmaj.170363

Canadian Pain Task Force. (2020). Working together to better understand, prevent, and manage chronic pain: What we heard. Health Canada. https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2020.html

Cheatham, S. W., Kolber, M. J., Cain, M., & Lee, M. (2015). The effects of self-myofascial release using a foam roll or roller massager on joint range of motion, muscle recovery, and performance: A systematic review. International Journal of Sports Physical Therapy, 10(6), 827–838. https://pubmed.ncbi.nlm.nih.gov/26618062/

Cramer, H., Lauche, R., Haller, H., & Dobos, G. (2013). A systematic review and meta-analysis of yoga for low back pain. The Clinical Journal of Pain, 29(5), 450–460. https://doi.org/10.1097/AJP.0b013e31825e1492

Furlan, A. D., Giraldo, M., Baskwill, A., Irvin, E., & Imamura, M. (2015). Massage for low-back pain. Cochrane Database of Systematic Reviews, (9), Article CD001929. https://doi.org/10.1002/14651858.CD001929.pub3

Gatchel, R. J., Peng, Y. B., Peters, M. L., Fuchs, P. N., & Turk, D. C. (2007). The biopsychosocial approach to chronic pain: Scientific advances and future directions. Psychological Bulletin, 133(4), 581–624. https://doi.org/10.1037/0033-2909.133.4.581

Geneen, L. J., Moore, R. A., Clarke, C., Martin, D., Colvin, L. A., & Smith, B. H. (2017). Physical activity and exercise for chronic pain in adults: An overview of Cochrane Reviews. Cochrane Database of Systematic Reviews, (4), Article CD011279. https://doi.org/10.1002/14651858.CD011279.pub3

Lesondak, D. (2026). The fascia connection: Discover the key to flexibility, longevity, and a pain-free life. Balance.

Lesondak, D., & Akey, A. M. (Eds.). (2025). Fascia, function, and medical applications (2nd ed.). CRC Press. https://doi.org/10.1201/9781032675886

Louw, A., Zimney, K., Puentedura, E. J., & Diener, I. (2016). The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature. Physiotherapy Theory and Practice, 32(5), 332–355. https://doi.org/10.1080/09593985.2016.1194646

Melzack, R. (2001). Pain and the neuromatrix in the brain. Journal of Dental Education, 65(12), 1378–1382. https://doi.org/10.1002/j.0022-0337.2001.65.12.tb03497.x

Melzack, R., & Wall, P. D. (1965). Pain mechanisms: A new theory. Science, 150(3699), 971–979. https://doi.org/10.1126/science.150.3699.971

Nijs, J., Apeldoorn, A., Hallegraeff, H., Clark, J., Smeets, R., Malfliet, A., Lluch Girbés, E., De Kooning, M., & Ickmans, K. (2015). Low back pain: Guidelines for the clinical classification of predominant neuropathic, nociceptive, or central sensitization pain. Pain Physician, 18(3), E333–E346. https://doi.org/10.36076/PPJ.2015/18/E333

Public Health Agency of Canada. (2026). Opioid- and stimulant-related harms in Canada: Key findings. Government of Canada. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/

Raja, S. N., Carr, D. B., Cohen, M., Finnerup, N. B., Flor, H., Gibson, S., Keefe, F. J., Mogil, J. S., Ringkamp, M., Sluka, K. A., Song, X.-J., Stevens, B., Sullivan, M. D., Tuttle, A. H., Ushida, T., & Staats, P. (2020). The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. Pain, 161(9), 1976–1982. https://doi.org/10.1097/j.pain.0000000000001939

Stecco, C. (2015). Functional atlas of the human fascial system. Churchill Livingstone. https://www.us.elsevierhealth.com/functional-atlas-of-the-human-fascial-system-9780702044304.html

Vlaeyen, J. W. S., & Linton, S. J. (2000). Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain, 85(3), 317–332. https://doi.org/10.1016/S0304-3959(99)00242-0

Wiewelhove, T., Döweling, A., Schneider, C., Hottenrott, L., Meyer, T., Kellmann, M., Pfeiffer, M., & Ferrauti, A. (2019). A meta-analysis of the effects of foam rolling on performance and recovery. Frontiers in Physiology, 10, Article 376. https://doi.org/10.3389/fphys.2019.00376

Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(3 Suppl.), S2–S15. https://doi.org/10.1016/j.pain.2010.09.030

World Health Organization. (2023). WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings. https://www.who.int/publications/i/item/9789240081789